PAL
vs
S
S&P/ASX 300
PAL
Over the past 12 months, PAL has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +7% growth.
Stocks Performance
PAL vs S&P/ASX 300
Performance Gap
PAL vs S&P/ASX 300
Performance By Year
PAL vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Palla Pharma Ltd
Glance View
Palla Pharma Ltd. manufactures and produces narcotic raw material for the international pharmaceutical industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-13. The firm's primary activities include production and distribution of Narcotic Raw Material (NRM),Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF) for supply to international pharmaceutical markets, and the production and distribution of poppy seed for supply to international culinary markets. The firm operates through two segments: Australia and Norway. Australia segment activities include Narcotic Raw Material and Poppy Seed production and distribution. Norway segment activities include Active Pharmaceutical Ingredient and Finished Dosage production and distribution. The firm has developed a water-based extraction technology, which is used in NRM production. The company sources its raw materials from Australian poppy growers in Tasmania, New South Wales, and Victoria.